Edwards Lifesciences Corp
NYSE:EW
Edwards Lifesciences Corp
Revenue
Edwards Lifesciences Corp
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Revenue
$5.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$17.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$42.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$8.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Edwards Lifesciences Corp
Revenue Breakdown
Breakdown by Geography
Edwards Lifesciences Corp
Breakdown by Segments
Edwards Lifesciences Corp
|
Total Revenue:
5.4B
USD
|
|
Transcatheter Aortic Valve Replacement:
4.1B
USD
|
|
Surgical Structural Heart:
981.3m
USD
|
|
Transcatheter Mitral And Tricuspid Therapies:
352.1m
USD
|
Edwards Lifesciences Corp
Glance View
Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.
See Also
What is Edwards Lifesciences Corp's Revenue?
Revenue
5.5B
USD
Based on the financial report for Mar 31, 2025, Edwards Lifesciences Corp's Revenue amounts to 5.5B USD.
What is Edwards Lifesciences Corp's Revenue growth rate?
Revenue CAGR 10Y
9%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for Edwards Lifesciences Corp have been 1% over the past three years , 4% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet